Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease
Retrieved on:
Thursday, September 23, 2021
Dementia, Adoption, Neurodegeneration, Probability, Environmental Modification Convention, Research, Review, Parkinson's disease, Diagnosis, Therapy, Genome, Cancer, Patient, Pathology, Professor, Population, Protein, Disease, CEO, University, Government budget balance, Mitchell Center, Amyloid, Peripheral nervous system, Oxidative stress, Brain, Incidence, Doctor of Philosophy, Howard Brody, Neuron, Medical imaging, Medical device
Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
Key Points:
- Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
- This knowledge is already fueling creation of novel prognostic tests for AD and may lead to the development of new therapies to counter disease progression."
- p53 is involved in the regulation of oxidative stress, which is implicated as one of the earliest events in AD.
- Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.